【摘要】 目的观察用西格列汀二甲双胍片治疗初诊断2型糖尿病的有效性和安全性。方法将2015年1月—2016年10月收治的40例新诊断2型糖尿病患者按照HbA1c水平分为A、B两组,采用二肽基肽酶-4(DPP-4)西格列汀二甲双胍复方制剂(50 mg西格列汀/500 mg盐酸二甲双胍)治疗,持续治疗30周。结果治疗24周后,空腹血糖,餐后2 h血糖、BMI、胰岛素释放水平与治疗前比较差异有统计学意义(P<0.05),血脂、肝肾功与治疗前比较差异无统计学意义(P>0.05)。无低血糖事件,未发生其它不良反应。结论西格列汀二甲双胍治疗初诊断2型糖尿病患者,可有效降低HbA1c及4个时点血糖(空腹及三餐后2 h血糖)。更多还原

【Abstract】 Objective To observe the effectiveness and safety of sitagliptin plus metformin in treatment of patients initially diagnosed with type 2 diabetes. Methods 40 cases of patients with type 2 diabetes were divided into the group A and group from January 2015 to October 2016 according to the HbA1c level, treated with dipeptidyl peptidase-4(DPP-4)sitagliptin plus metformin compound preparation(50 mg sitagliptin/500 mg metformin hydrochloride), for 30 weeks in a row. Results After 24 weeks, the differences in the fasting blood glucose, postprandial 2 h blood glucose, BMI, insulin release level before and after treatment were statistically significant(P<0.05), and the differences in the blood liquid, liver and renal functions before and after treatment were not statistically significant(P>0.05), without the hypoglycemia events and other adverse reactions. Conclusion The sitagliptin plus metformin in treatment of patients initially diagnosed with type 2 diabetes can effectively reduce the HbA1c and blood glucose levels at four time points(fasting blood glucose and postprandial 2 h blood glucose).更多还原